Marshall Wace LLP Sells 81,216 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Marshall Wace LLP lowered its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 7.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,079,757 shares of the biopharmaceutical company’s stock after selling 81,216 shares during the period. Marshall Wace LLP’s holdings in Intra-Cellular Therapies were worth $90,181,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of ITCI. GAMMA Investing LLC increased its holdings in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 240 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Intra-Cellular Therapies during the fourth quarter valued at about $96,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Intra-Cellular Therapies in the third quarter worth about $97,000. Covestor Ltd lifted its position in shares of Intra-Cellular Therapies by 15.9% in the fourth quarter. Covestor Ltd now owns 2,099 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 288 shares in the last quarter. Finally, Barlow Wealth Partners Inc. bought a new position in Intra-Cellular Therapies during the fourth quarter valued at approximately $184,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. StockNews.com initiated coverage on Intra-Cellular Therapies in a research note on Sunday. They issued a “hold” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $106.23.

Intra-Cellular Therapies Stock Performance

ITCI opened at $131.87 on Thursday. The stock’s 50 day moving average price is $130.58 and its 200-day moving average price is $105.16. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.98. The stock has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. As a group, analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.